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Abstract
Background: Recombinant interferon treatment can result in several common side effects including fever and injection-site
pain. Patients are often advised to use acetaminophen or other over-the-counter pain medications as needed. Little is
known regarding the transcriptional changes induced by such co-administration.
Methodology/Principal Findings: We tested whether the administration of acetaminophen causes a change in the
response normally induced by interferon-b treatment. CD-1 mice were administered acetaminophen (APAP), interferon-b
(IFN-b) or a combination of IFN-b+APAP and liver and serum samples were collected for analysis. Differential gene
expression was determined using an Agilent 22 k whole mouse genome microarray. Data were analyzed by several
methods including Gene Ontology term clustering and Gene Set Enrichment Analysis. We observed a significant change in
the transcription profile of hepatic cells when APAP was co-administered with IFN-b. These transcriptional changes included
a marked up-regulation of genes involved in signal transduction and cell differentiation and down-regulation of genes
involved in cellular metabolism, trafficking and the IkBK/NF-kB cascade. Additionally, we observed a large decrease in the
expression of several IFN-induced genes including Ifit-3, Isg-15, Oasl1, Zbp1 and predicted gene EG634650 at both early and
late time points.
Conclusions/Significance: A significant change in the transcriptional response was observed following co-administration of
IFN-b+APAP relative to IFN-b treatment alone. These results suggest that administration of acetaminophen has the potential
to modify the efficacy of IFN-b treatment.
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Introduction
Type I interferons (IFNs) are key cytokines in the activation of
the innate immune response and induce a cascade of anti-viral,
anti-proliferative and immunomodulatory responses (as reviewed
in [1,2]). Briefly, Type I interferons signal through the
coordinated activation of Janus (JAK) family kinases and Signal
Transducers and Activator of Transcription (STAT) family
members. IFN-mediated signal transduction begins when the
IFN Alpha receptor (IFNAR) is dimerized by IFN, resulting in
auto-phosphorylation of receptor-associated JAK tyrosine kinas-
es. Phosphorylated JAKs activate associated STAT proteins
which translocate to the nucleus where they induce transcription
through binding to different promoter elements. Additionally,
IFN-receptor dimerization can directly activate PI 3-kinase/Akt,
Raf-1/ERK and p38 MAP kinase pathways. Beyond the
induction of transcription through IFN activity the convergence
of signals with other pathways such as the IkK/NF-kBc a n
modify the transcriptional response. For example, IkK-related
kinases are required for activation of Interferon Regulatory
Factors (IRFs) 3 and 7 while some promoters require both NF-kB
and IRF-3 binding [3,4].
In some instances native IFN signalling is insufficient to induce
the necessary immune response. It has been repeatedly demon-
strated that exogenously supplied interferon can further stimulate
transcription, overcoming a previously moribund response. Due to
the pleiotropic effects induced by IFNs, recombinant interferon
therapy has been approved to treat a variety of medical conditions
including viral infections, various cancers and autoimmune
disorders, including multiple sclerosis (MS) [5,6,7]. Treatment of
relapsing-remitting MS cases with recombinant IFN-b can induce
a broad shift in the auto-immune response, changing it from
primarily a cytotoxic-Th1 to a humoral-Th2 response, and shifting
its focus from the central nervous system to the periphery [8].
While a Th1-driven response can be an essential component of the
immune response to intracellular pathogens, it leads to a
significant increase in cell lysis and is of primary concern in
auto-immune diseases.
Given the potent immunoregulatory role of interferon-subtypes,
it is not surprising that recombinant interferon therapy has a
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injection-site reactions that can result in dose limitations or
cessation of treatment [9]. In order to alleviate undesired side
effects of IFN therapy, patients are routinely advised to self-
medicate with analgesics such as acetaminophen (APAP) [10].
Acetaminophen (APAP) is an antipyretic and analgesic which is
commonly used for the relief of fever, headaches and flu-like
symptoms. The effects of APAP are mediated through inhibition of
prostaglandin H2 synthase (PGHS), but this activity does not affect
all cells and tissues equally [11]. While endothelial cells and
neurons are extensively affected by APAP, little change is observed
in other cell types such as platelets or activated leukocytes [11].
The casual use of APAP has raised concerns due to its potential
to effect changes in the desired immune response, although it is not
an anti-inflammatory medication. APAP administration reduces
antibody production and B-cell activation in mice indicating that
APAP modifies specific arms of the immune system [12]. APAP
has also been observed to diminish vaccine efficacy during
childhood immunizations. Children who were administered
prophylactic APAP during immunization had lower mean
antibody titers and less frequent vaccine responses [13]. Interest-
ingly a similar study examining an elderly cohort found no
difference in the response to an influenza vaccine when co-
administered with APAP [14]. Prolonged illness, virus shedding
and decreased antibody responses are associated with continual
APAP treatment during rhinovirus infections indicating an effect
of APAP on the host antiviral response [15]. The apparent
systematic depression of aspects of the humoral immune response
following APAP treatment raises questions as to whether APAP
can interfere with the response to recombinant interferon therapy.
Ozaki et al demonstrated that the induction of indoleamine 2,3-
dioxygenase by IFN-a was substantially reduced when adminis-
tered with APAP [16]. In vitro, APAP has been shown to diminish
the IFN-induced antiviral response of cultured mammalian cells
[17]. However, investigations into the combination IFN-a and
APAP in human volunteers found no evidence for a change in
either the antiviral activity or in the production of 2959
oligoadenylate synthetase (OAS2) from isolated PBMCs [18,19].
The discrepancies between these observed effects may be due to
APAP having a limited effect on some cell populations or
conversely affecting only specific genes or proteins.
DNA microarrays allow the transcription profile of the entire
genome to be assessed. They have been extensively employed to
examine the transcriptional changes induced by recombinant IFN
or APAP on cell lines, purified cell types, and whole tissues. Given
seeming discrepancies between various studies on possible
interference between APAP and the IFN-response we felt that
an exploratory investigation into whether APAP is capable of
modifying just the transcriptional response induced by IFN could
be fruitful. Since changes induced by APAP may occur only on a
few genes out of the wide number altered by IFN-b we felt that this
technology would be an excellent tool to study the effects of co-
treatment. The primary aim of this study was to determine how a
single, sub-toxic dose of APAP alters the profile of IFN-b induced
gene transcription.
Materials and Methods
Animals
Adult male CD-1 mice (Charles River Laboratories, Montreal,
QC) from 6–8 weeks old were used in all experiments. Animals
were housed in autoclaved cages in a pathogen-free environment
for 1 week prior to use. Mice were provided access to autoclaved
food (Purina Lab Chow #5001) and water. All experiments were
conducted according to CCAC guidelines and approved by
Health Canada’s Animal Care Committee.
Animal Protocol
Prior to treatment mice were fasted overnight (12 h). Access to
food was restored following I.P. administration of treatment. Mice
were divided into four groups of 12 and given one of following
treatments: 1) vehicle control (25 mM Hepes, pH 6.0, 500 mM
NaCl, 6% glycerol, 0.5% ethanol, 0.05% mouse serum albumin; 2)
APAP (Sigma-Aldrich Canada, Oakville, ON) (300 mg/kg)
dissolved in vehicle; 3) IFN-b (3.75610
7 U/kg) dissolved in
vehicle; 4) APAP (Sigma-Aldrich Canada, Oakville, ON)
(300 mg/kg)+IFN-b (PBL Biomedical Laboratories, Piscataway,
NJ) (3.75610
7 U/kg) dissolved in vehicle.
Sera and Tissue Collection
Retro-orbital blood samples (50 mL) were collected 24 h prior to
treatment. Mice were anesthetised with isofluorane 1.5 or 4 hours
following treatment (6 mice per time point/treatment group).
Total blood was collected by cardiac puncture. Blood samples
were transferred to serum separator tubes (Becton Dickinson,
Franklin Lakes, NJ) and centrifuged. Serum was frozen in liquid
nitrogen and stored at 280uC until analysis. Liver lobes were cut
into <200 mg sections, frozen in liquid nitrogen and stored at
280uC until analysis.
Toxicity Tests
Hepatic injury was evaluated by measuring the activities of the
hepatic enzymes alanine amino transferase (ALT), serum alkaline
phosphatase (ALKP), aspartate aminotransferase (AST) and total
bilirubin (TBil) activity in the serum using VetTest arrays on a
VetTest Chemistry Analyzer (Idexx Laboratories, UK). Tests were
performed according to the manufacturer’s instructions.
RNA Extraction and Purification
Total RNA was isolated from liver samples using TRIzol
reagent (Invitrogen, Burlington, ON) and purified using RNeasy
Spin Columns (Qiagen, Mississauga, ON). RNA quantity and an
initial quality estimate were determined using a ND-1000
spectrophotometer (Nanodrop Ltd, Willmington, DE). RNA
quality was then assessed using the Agilent 2100 Bioanalyzer
(Agilent Technologies, Mississauga, ON) and only samples with a
RNA integrity number (RIN) of 8 or greater were employed.
Microarray Hybridization
A reference design was used for the microarray experiment [20,21],
with experimental RNA samples labelled with Cy5 and technical
replicates of a commercially-available universal reference RNA
sample (URR; Stratagene, La Jolla, CA) labelled with Cy3.
Cyanine-labelled cRNA (Perkin Elmer Life Sciences, Waltham,
Massachusetts) was produced from individual liver samples (2 mg)
from 40 mice (two time points, comprised of 4 treatment groups with 5
mice each) and URR using Low RNA Input Fluorescent Amplifica-
tion kits (Agilent Technologies) according to the manufacturer’s
instructions. Labelled RNAs were co-hybridized to Agilent 22 k
oligonucleotide microarrays (Mouse V2 G4121B, Agilent Technolo-
gies) at 60uC for 17 h. Hybridized arrays were washed, fixed and
scanned on a ScanArray Express (Perkin-Elmer Life Sciences) and
data acquired using Imagene 5.5 (Biodiscovery Inc., El Segundo, CA).
Statistical Analysis of Microarray Data
All pre-processing of the data was conducted using R [22,23].
The median signal intensities were normalized using the global
Acetaminophen and Interferon-b
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MAANOVA library [24]. Ratio intensity plots were constructed
for the raw and normalized data for each array and hierarchical
clustering using complete and single linkages were generated to
identify and exclude microarrays with poor data quality.
Differentially expressed genes were identified using the
MAANOVA library by relative intensity. An ANOVA model
included the main effect of treatment, time and a treatment by
time interaction. The date of hybridization was used in the model
as block effect. The Fs statistic [25], a shrinkage estimator, was
used for the gene-specific variance components and the associated
p-values for all the statistical tests were estimated using the
permutation method (10,000 permutations with residual shuffling).
These p-values were then adjusted for multiple comparisons by
using the false discovery rate approach (FDR) [26]. The least-
squares means were used to estimate the fold changes for each
pair-wise comparison. The complete list of the probes used and
expression analysis are submitted to Gene Expression Omnibus
GEO # GSE18949. Genome-wide expression patterns of all genes
with an FDR,0.05 were initially analyzed using the Pearson
correlation/clustering function in GeneSpring GX10.02 (Agilent
Technologies, Mississauga ON).
DAVID Analysis
Gene Ontology analysis was performed by DAVID (Database
for Annotation Visualization and Integrated Discovery, NIAID/
NIH), which was used to cluster gene ontology term enrichment
[27,28]. Probes that were identified as differentially regulated
during initial microarray analyses (Treatment Effect FDR#0.05)
were sorted by group (Group vs. Control FDR#0.05) and a Fold
change (+/2 1.5). These probe lists were converted to David IDs
and analyzed using medium classification stringency.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis (GSEA) of the lowess normalized
data was performed using the GSEA software package [29,30]. A
ranked list of genes from the microarray data set was generated
based on their metric to noise ratio. Curated biological pathway
gene sets from the Molecular Signature Database (MsigDB) were
screened against the ranked gene list and an order enrichment
score (ES) was calculated for each gene set. This value is derived
by walking along the ranked list using a cumulative sum statistic
which increases when a member of a specific gene set is found in
the ranked gene list and is penalized when it does not appear in the
gene set [30]. The GSEA parameters used included metric, signal
to noise; enrichment scoring statistic, weighted; permutation type,
gene set; permutation number, 1000; and gene size restrictions, 15
minimum and 500 maximum. To adjust for multiple hypothesis
testing, the ES for each gene was normalized to account for the
size of the set, yielding a normalized enrichment score (NES). The
proportion of false positives was controlled by calculating the false
discovery rate (FDR) corresponding to each NES [26]. After
running GSEA, the leading edge analysis feature of the software
was used to examine the genes in the leading edge subsets of
selected enriched gene sets.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Taqman gene expression assays (Applied Biosystems)
[Mm00516005_m1 (Hmox1), Mm01601704_g1 (Krt18),
Mm00456139_m1 (Blnk), Mm00460961_m1 (Oas2) and
Mm00549143_m1 (Irak2), Mm01613158_m1(EG634650),
Mm01247052_m1 (Zbp1), Mm01704846_s1 (Ifit-3),
Mm00455082_m1 (Oasl1), Mm01705338_s1 (ISG15)] were used
to examine the relative quantity of specific RNAs in each
treatment group. Total RNA (2.5 mg per sample) was reverse
transcribed and quantified on an Applied Biosystems 7500 Real-
Time PCR instrument (Applied Biosystems) according to the
manufacturer’s instructions. Beta-actin was used as an endogenous
control, threshold cycles were averaged and expression levels were
calculated as relative to vehicle control data.
Results
Experimental Design
Pilot studies were conducted in which mice were treated with
varying doses of APAP or IFN-b (APAP 100–550 mg/kg, IFN-b
1610
6–1610
8 U/kg) and liver and sera were collected at several
time points (1.5–24 h). During these pilot studies hepatotoxicity
was evaluated by microscopic examination of formalin-fixed
hepatic tissue as well as by assessment of serum ALT and AST
levels. No evidence for hepatotoxicity was observed in samples
collected 1.5, 4, 8 and 24 h following treatment with any drug
dose (data not shown). This was expected as young CD-1 mice are
highly resistant to APAP-mediated hepatotoxicity and do not
suffer toxic effects when administered APAP at these doses
[31,32]. As such, we selected one dose (APAP 300 mg/kg and
IFN-b 3.75610
7 U/kg) and two time points (1.5 and 4 h) based on
the transcriptional responses of several target genes in the
treatment groups as measured by RT-PCR (data not shown).
These time points were consistent with previously published
studies on mRNA expression following APAP or IFN-b treatment
[33,34]. RNA was extracted from the large liver lobe and applied
to microarray and RT-PCR analysis as described in the Materials
and Methods.
Hepatotoxicity induced by treatment
To monitor for any overt hepatotoxic events ALT, ALKP, AST
and TBil assays were performed on the pre- and post-treatment
serum of CD-1 mice at 1.5 h and 4 h time points. The levels of
ALT, ALKP, AST or TBil did not differ significantly in mice
receiving APAP, IFN-b or IFN-b+APAP from mice in the vehicle
control group or untreated mice (data not shown). As expected, no
overt signs of hepatotoxicity were observed.
Microarray Analysis
Total mRNA isolated from murine hepatic tissue in mice
treated with APAP alone, IFN-b alone or a combination of IFN-
b+APAP were compared to those of mice treated with Vehicle
alone at 1.5 and 4 hours post-treatment. Five samples were
analyzed per treatment group (GEO # GSE18949). We identified
1900 probes that detected a significant change in transcript levels
(FDR-adjusted p-value of less than 0.05) due to one or more
treatments relative to the vehicle control. A correlation/cluster
analysis was applied to all significant genes (1900 probes) (Figure 1).
Samples clustered into two main branches with vehicle and APAP
treated mice on one branch, and IFN-b and IFN-b+APAP treated
mice on the other. There was some clustering within time points,
but the analysis revealed that APAP causes very little change in
overall gene expression, while IFN-b and IFN-b+APAP treatments
induce similar changes in transcript levels.
The 1900 probes that were considered significantly different
from vehicle are displayed in Table S1. Of these, 784 probes
which have a minimum difference of at least 1.5 fold from vehicle
are summarized according to specific treatment and time groups
(Table 1). This analysis revealed that very few genes are
significantly affected by APAP alone at either 1.5 h (8 genes) or
Acetaminophen and Interferon-b
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early and late time points with 165 and 133 probes detecting
altered transcript levels respectively. Relative to the IFN-b
treatment group, the combined treatment (IFN-b + APAP)
resulted in a large increase (3 fold) of the number of genes with
FDR p-values,0.05 at both 1.5 h and 4 h time points, suggesting
that APAP significantly alters the gene expression pattern induced
by interferon treatment (Table 1). At 1.5 hours the transcriptional
response is balanced or up-regulated in IFN-b and IFN-b+APAP
groups while at four hours the majority of transcripts were down-
regulated in both sets. Previous studies have demonstrated similar
temporal effects on transcription induced by APAP or IFN-b alone
[33,35]. The gene lists created following microarray analysis
largely agreed with previously published results following recom-
binant interferon-b treatment [35,36]. The same was not true for
APAP alone. Where we found very few genes responsive to APAP
others have demonstrated large number of gene expressed
following similar treatments [33]. Likely factors contributing to
this include the age of the CD-1 mice employed herein as well as
the conservative hierarchical approach employed which would not
have counted genes which showed a large degree of variability
between sample sets.
To examine the specific effects of APAP on IFN-b induced gene
expression we collated all IFN-altered genes (Table S1) with a 1.5
Figure 1. Correlation/cluster analysis of significantly altered probes. Samples clustered into two branches with vehicle and APAP treated
mice on the left, and IFN-b and combined treatment on the right. Each column represents a single sample. Colours indicate high relative signal
intensity (red), low relative signal intensity (green), and similar signal intensity (black) in the reference and sample channels. The branches of the tree
are coloured by treatment.
doi:10.1371/journal.pone.0011031.g001
Table 1. Probes that detected significantly (FDR #0.05)
changed transcript levels and had a 1.5-fold difference from
the vehicle control.
Total Up-regulated Down-regulated
1.5 h 4 h 1.5 h 4 h 1.5 h 4 h
APAP 82 2 0 6 2
IFN-b 165 133 79 48 86 85
IFN-b + APAP 467 458 314 103 153 355
The number of probes that detect a significant change in the transcripts relative
to the vehicle control is displayed. Table 1 displays total probes.
doi:10.1371/journal.pone.0011031.t001
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and IFN-b+APAP treatment sets. At 1.5 hours post-treatment 165
genes have significantly altered expression, 93 (52%) of which,
have lower expression (less-positive or more negative) in the IFN-
b+APAP treatment group. Specifically, 51 out of the 79 (65%) up-
regulated genes and 42 of the 86 (49%) down-regulated genes have
lower expression in the combined treatment. This pattern is
accentuated at the 4 h time point where of the 133 genes altered
by IFN-b, 110 (83%) have lower-expression, including 45 of 48
(94%) up-regulated genes and 65 of 85 (76%) down-regulated
genes, in IFN-b+APAP co-treated mice.
To look at those genes with the largest differences we curated
the list of significantly expressed IFN-b genes (Table S1) for those
that showed at least a 1.5 fold-difference between IFN-b and IFN-
b+APAP treatment sets (Table 2). This analysis highlighted several
treatment effects. At 1.5 hours 16 of 79 (20%), while at 4 hours, 12
of 48 (25%), of IFN-b up-regulated genes, were differentially
expressed by at least 1.5-fold in IFN-b+APAP treated mice. In all
cases expression was lower in the co-treated mice. Five genes were
common between these two time points, Ifit-3, Isg15, Oasl1, Zbp1
and a predicted gene EG634650 (Table 2). Amongst the 85 and 86
genes down-regulated by IFN-b at the 1.5 and 4 h time sets
respectively only four genes at each time point demonstrated a 1.5-
fold difference when mice received both IFN-b+APAP (Table 2).
The four genes at the 1.5 hour time point were elevated (less
down-regulated) while the four genes observed at 4 hours were
more down-regulated in the IFN-b+APAP treatment group and
no genes were in common between the two time points. This data
suggests while there may be a specific effect of APAP on several
genes up-regulated by IFN-b, the predominant effect is a broad,
small depression of transcription. As we observe in Table1, this
broad effect coincides with an overall global dampening of
transcription in IFN-b+APAP treated samples.
Semi-quantitative real time RT-PCR was performed on the
liver RNA samples harvested from the treated mice in order to
confirm the expression levels of several genes identified using the
Agilent 22 k microarrays (Table 3). These results confirmed the
pattern of expression observed including the significant changes in
the expression observed between treatment groups.
Ontology Analysis
In order to explore common themes of affected genes we
employed DAVID (Database for Annotation, Visualization and
Integrated Discovery, NIAID), an on-line resource that identifies
enrichment of genes with specific gene ontology (GO) terms
[27,28]. Table 4 displays the results of this analysis, and includes
biological pathways from the top annotation clusters enriched in
each treatment group by analysis of the probes with fold-changes
greater than 1.5. At 1.5 hours, genes down-regulated by APAP
treatment were enriched in one functional group representing lipid
biosynthesis. Genes up-regulated by IFN-b treatment at this time
point clustered to several functional groups all involved in immune
responses, while down-regulated genes grouped strongly with
cellular biosynthesis and metabolic processes. Genes up-regulated
by IFN-b+APAP co-treatment were over-represented in 8
functional groups predominately involved in cell signalling and
development, while down-regulated genes clustered strongly with
cellular metabolism and biosynthesis pathways (Table 4). No
clusters of terms related to immune responses (such as immune
response, response to virus, defence response, etc.), were enriched
amongst the up-regulated genes that exhibited at least a 1.5 fold
change in expression. However, when the IFN-b+APAP set was
repeated using only probes showing$2 fold-changes relative to
vehicle we detected enrichment in one functional group, a GO
cluster of immune response pathways (data not shown). Therefore,
many of the observed differences between IFN-b and the
combined treatment group are likely due to additional genes up-
regulated in the IFN+APAP set as opposed to the specific absence
of immune related genes.
At the 4 h time point genes up-regulated after IFN-b treatment
clustered with two GO biological processes, both involved in the
host immune response. Only one biological process group, lipid
metabolism, was enriched by genes down-regulated during IFN-b
treatment. GO pathways represented by genes up-regulated by
IFN-b+APAP treatment were identical to the IFN-treatment
group. Genes down-regulated by IFN-b+APAP clustered into 27
functional groups which were overwhelmingly associated with
cellular metabolism and gene expression pathways, such as RNA
processing or translation (Table 4). Overall these data suggest that
the largest effect of APAP during IFN-b treatment is to cause a
short-term up regulation of sensory and developmental genes
but by 4 hours repress genes involved in transcription and
biosynthesis.
Gene Set Enrichment Analysis
Evaluation of microarray data using MAANOVA statistics with
an FDR-adjusted p-value of 0.05 is a conservative approach for the
identification of differential gene expression. It has been suggested
that such an approach can result in a large number of false negative
findings and the loss of valuable data [37]. Furthermore, DAVID
doesn’t take into consideration gene expression levels limiting
analysis possible given the broad similarity of effect (Figure 1).
Therefore, we re-evaluated some of our results using the Gene Set
Enrichment Analysis (GSEA) software package to improve our
understanding of the gene sets or pathways that responded to
treatment. As the overall results between the two time points were
similar we chose to limit this analysis to the 4 hour dataset. The
results of the GSEA analyses are shown in Table 5 at an FDR,0.1
with the full results shown in Table S2. APAP treatment alone
showed no significant differences from that of the vehicle control
group, in broad agreement with our previous analyses. GSEA
analysis of the IFN-b treatment group identified 23 pathways that
were up-regulated relative to vehicle control (Table 5). Of these 23
pathways, 15 are directly related to the immune response, 3 to
proliferation and the remainder to signal transduction, protein
transport and protein modification processes. IFN-b treatment also
led to the down regulation of 4 pathways involved in transcription/
translation and DNA repair. GSEA analysis of IFN-b+APAP versus
vehicle (I.A. v V.) revealed a significant deviation from the IFN-b
induced response. Genes up-regulated by IFN-b+APAP versus
vehicle were involved in 2 biological pathways both related to the
immune response related (Table 5). No pathways were identified as
down-regulated in the I.A. datasets.
We also directly compared the IFN-b+APAP treatment group
to the IFN-b treatment group (I.A.vs I.). We detected no positive
enrichment of pathways in this comparison but did find 14
pathways that were down-regulated by IFN-b+APAP relative to
IFN-b alone. These were predominately transcription and
transportation related pathways in addition to the IkB/NF-kB
cascade.
Leading edge analysis was conducted on the gene sets enriched
at FDR,0.1. The results for the analysis of IFN-b+APAP versus
IFN-b are displayed in Figure 2. Leading edge analysis assumes
that genes that contribute to multiple pathways will be of greater
interest than those that only contribute to one pathway.
There are 178 genes that contribute to the enrichment of 14
down-regulated pathways when IFN-b+APAP is compared to IFN-
b (Figure 2). Of these genes, 24 contribute to 5 or more pathways
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Lman2L, Stx18, all of which are involved in cellular membrane
trafficking events. Additional genes that were enriched in multiple
biological pathways include Fusip1, Sip1 (Gemin2), Gemin5,
Gemin7, Sf3A1, Sf3A2, Sf3A3, SfrS1, SfrS6, SfrS10, Slu7, Snw1,
Prpf31 and Crnkl1 all of which are involved in RNA processing.
Discussion
This study has demonstrated the effect of APAP on the murine
hepatic response to IFN-b in vivo using a whole genome
microarray. Over 1900 genes from the large liver lobe of mice
were significantly responsive to treatment with IFN-b, APAP or
IFN-b+APAP; of these 784 were differentially expressed at a level
of 1.5 fold over vehicle control. The response to IFN-b in live
animals supported previous observations made in cell culture [36].
Many genes were differentially expressed when APAP was co-
administered with IFN-b. This was in contrast to the very few
genes that were responsive to APAP alone. Cluster analysis
revealed that APAP and control liver samples shared very similar
expression profiles, while IFN-b and IFN-b+APAP profiles were
highly correlated. However, the synergistic effect of APAP on the
Table 2. List of genes altered by IFN-b with a 1.5 fold difference in co-treatment.
Lower Expression in co-treatment
Time
Set Gene Description
IFN-b
1.5 h
IFN-b + APAP
1.5 h IFN-b 4 h IFN-b + APAP 4 h
Both Ifit3 Interferon-induced protein with tetratricopeptide repeats 3, [NM_010501] 12.79 5.8 49.55 22.85
Both Isg15 ISG15 ubiquitin-like modifier,[NM_015783] 9.73 5.71 20 12.3
Both Oasl1 29–59 oligoadenylate synthetase-like 1, [NM_145209] 5.19 3.11 13.29 7.33
Both Zbp1 Z-DNA binding protein 1, [NM_021394] 3.72 2.25 13.1 6.7
1.5 Rsad2 Radical S-adenosyl methionine domain containing 2, [NM_021384] 5.61 3.56 12.85 10.02
4 Usp18 Ubiquitin specific peptidase 18, [NM_011909] 4.28 3.12 12 7.85
1.5 Cxcl10 Chemokine (C-X-C motif) ligand 10, [NM_021274] 14.21 7.52 9.75 8.85
1.5 Ifi47 Interferon gamma inducible protein 47, [NM_008330] 3.87 2.46 6.88 4.87
Both EG634650 Predicted gene, EG634650, [NM_001039647] 4.78 2.29 6.52 4.09
1.5 Socs1 Suppressor of cytokine signaling 1, [NM_009896] 6.22 4.11 5.43 5.2
1.5 Parp14 Poly (ADP-ribose) polymerase family, member 14, [NM_001039530] 3.83 2.45 4.35 3.99
4 2310016F22Rik RIKEN cDNA 2310016F22 gene, [NM_173743] 1.03 21.5 3.94 1.73
1.5 Mx1 Myxovirus (influenza virus) resistance 1, [NM_010846] 3.6 2.08 3.42 3.12
4 Nmi N-myc (and STAT) interactor, [NM_019401] 1.17 21.1 3.09 1.79
4 Serpina6 Serine (or cysteine) peptidase inhibitor, clade A, member 6, [NM_007618] 21.05 1.12 2.9 1.53
4 Blnk B-cell linker, [NM_008528] 21.01 21.34 2.58 1.19
4 Batf2 Basic leucine zipper transcription factor, ATF-like 2, [NM_028967] 2.09 1.54 2.16 1.43
1.5 Adm Adrenomedullin, [NM_009627] 2.02 1.35 2.11 1.81
4 Myo5b Myosin Vb, [NM_201600] 21.22 21.26 2 21.02
1.5 Zbtb5 Zinc finger and BTB domain containing 5, [NM_173399] 1.77 1.11 1.28 1.1
1.5 Olfr578 Olfactory receptor 578, [NM_147115] 2.29 1.15 1.11 1.1
1.5 D330038O06Rik RIKEN cDNA D330038O06 gene, [NM_177899] 6.06 1.47 21.1 21.01
1.5 Rnf186 Ring finger protein 186, [NM_025786] 2.09 1.37 21.4 21.39
4 Mtmr4 Myotubularin related protein 4, [NM_133215] 21.02 1.03 21.63 22.76
4 Mettl7b Methyltransferase like 7B, [NM_027853] 21.13 21.2 21.69 22.66
4 Grb7 Growth factor receptor bound protein 7, [NM_010346] 21.81 21.95 21.94 23.12
4 Fasn Fatty acid synthase, [NM_007988] 23.19 23.58 22.42 23.72
Elevated Expression in co-treatment
Time
Set Gene Description
IFN-b
1.5 h
IFN-b + APAP
1.5 h IFN-b 4 h IFN-b + APAP 4 h
1.5 Hsd3b3 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 3, [NM_001012306]
22.65 21.44 21.23 21.54
1.5 Dbp D site albumin promoter binding protein, [NM_016974] 22.47 21.48 22.27 22.13
1.5 G6pc Glucose-6-phosphatase, catalytic, [NM_008061] 210.51 25.37 22.25 21.75
1.5 EG624219 Predicted gene, EG624219, [NM_001080940] 22.31 21.44 1.56 21.43
Time Set indicates the time point at which a 1.5-fold or greater change is observed between IFN and IFN+APAP samples. Values are the relative expression level of
treatment compared to vehicle control. Bolded numbers indicate FDR ,0.05.
doi:10.1371/journal.pone.0011031.t002
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magnitude of the IFN- b transcriptional response. It is likely that
the synergistic effect we observe is due to the specific effect of
APAP on gene expression rather than liver injury. No hepatotox-
icity was detected and none was expected as 6–8 week old CD-1
mice have been shown to maintain liver activity in the presence of
higher APAP doses than administered in this study [31,32].
Of the genes significantly up-regulated by IFN-b treatment the
majority were lower in IFN-b+APAP samples including 45 of the
48 genes significantly elevated 4 hours post-treatment. Signifi-
cantly, 25% of these genes are diminished by 1.5 fold or greater.
While a large number of genes down-regulated by IFN-b
treatment are further diminished by APAP at this time point only
4 (5%) were reduced by 1.5-fold. There may be multiple factors
governing the depression of the IFN-b response. Some genes up-
regulated by IFN-b have significantly diminished expression
following APAP administration suggesting a specific effect on
one or several genes involved in IFN-b signalling. However, the
observed effects are small on the majority of IFN-b-responsive
genes and likely due to the negative effect that IFN-b+APAP has
on genes involved in RNA processing and transcription.
Amongst the 27 IFN-b induced genes whose expression was
diminished 1.5 fold or more by APAP co-treatment five genes, Ifit-
3, Isg-15, Oasl1, Zbp1 and EG634650 or GBP11 are detected at
both time points. Ifit-3 (Rig-G) is an RNA helicase induced via
multiple signals including STAT2/IRF-9 and double-stranded
RNA [38]. Ifit-3 is involved in the activation of cytosolic IRF-3
and NF-kB [39] as well as the down-regulation of c-Myc [40]. The
down-regulation of c-Myc may be an important function of Ifit-3
as previous studies have demonstrated that c-Myc expression can
impair the IFN response and in particular, suppress the NF-kB
cascade [41,42]. APAP has been demonstrated to induce c-Myc
expression suggesting one means by which APAP may globally
interfere with effects of recombinant IFN-b. Furthermore, APAP
inhibits degradation of I-kB thus interfering with NF-kB activation
[43] suggesting another means by which APAP could interfere
with IFN signalling. A second inhibitor of c-Myc activity, Nmi,
was significantly diminished at 4 h, although not at 1.5 h post-
treatment (Table 2).
Isg15, an ubiquitin–like enzyme had substantially diminished
expression following co-treatment at both time points, while the
Isg-15 specific protease, Usp18 was only diminished by more than
1.5-fold at 4 hours. Isg15 and Usp18 are interferon-induced
ubiquitin conjugating/deconjugating proteins which down-regu-
late the JAK/STAT pathway in a negative feedback loop [44]. In
addition to targeting IFN-induced proteins, such as Ifit-3, Mx1
and PKR, Isg15 also targets proteins from a range of other
pathways for degradation including those involved in RNA
splicing, transcription and translation [45].
Oasl1, is a member of the 29–59 oligoadenylate synthetase
family, however it lacks obvious OAS activity. Oasl1, however,
does possess antiviral properties against some RNA viruses,
although the specific mechanism by which it operates is unclear
[46].
Zbp1 is a cytosolic ‘‘danger’’ sensor that activates IRF3 and NF-
kB pathways in response to cytoplasmic DNA [47]. Zbp1
activation of IRF3 is dependent on the recruitment of TBK-1
(TANK-binding kinase-1) and an IkB kinase, both of which are
involved in NF-kB activation.
The predicted sequence EG634650 has been identified as
belonging to the guanylate binding protein family, one of three
types of GTPases induced by IFN sub-types. Identified family
members have antiviral effects in certain cell lines and can be
induced by both IRF-1 and STAT1 [48].
The depression of genes that can positively or negatively
regulate IFN-signalling in addition to downstream IFN targeted
genes suggest that lower overall signal transduction occurs when
IFN-b is administered with APAP. No differences, however, were
observed in the expression of IFNAR1 or 2, STAT1, STAT2 or
STAT3. One explanation may be that while the expression of
these genes remains constant the activity of one or more of the
STAT proteins is depressed in the presence of APAP.
Ontology analysis highlighted differences in biological processes
that were affected by the individual treatments relative to the
combined treatment. An important example is the response of G-
protein coupled receptors (GPCRs). The most highly represented
responsive genes in the DAVID analysis were GPCRs and these
were exclusively enriched in the combined treatment group at
1.5 hours. The majority of these GPCRs are components of the
odorant sensory system. Olfactory receptors (ORs) are the largest
mammalian gene family with over 1000 representatives in the
murine genome [49]. ORs are expressed in a variety of cells and
tissues but their contributions to signalling outside of the odorant
system are largely undefined [50,51]. Several studies have
Table 3. Confirmation of selected genes using RT-PCR.
Encoded Protein/Gene Symbol Microarray RT-PCR
APAP IFN-b IFN-b+APAP APAP IFN-b IFN-b+APAP
Heme oxygenase (decycling) 1 Hmox1 2.7 21.5 2.3 9.6 23.8 12.1
Keratin 18 Krt18 21.3 1.1 22.0 21.7 1.1 22.0
B-cell linker Blnk 21.0 2.6 1.2 22.3 10.1 6.1
29–59 Oligoadenylate synthetase 2 Oas2 1.0 1.8 1.3 21.3 26.8 13.0
Interleukin-1 receptor-associated kinase 2 Irak2 21.1 21.0 21.6 21.5 22.8 24.0
EG634650 EG 21.2 6.5 4.1 23.6 95.3 24.7
Interferon-induced protein with tetratricopeptide repeats 3 Ifit3 21.1 49.6 29.9 23.1 376.9 109.2
Interferon Stimulated Gene 15 ubiquitin-like modifier Isg15 21.3 20.0 12.3 21.2 245.1 96.1
29–59 Oligoadenylate synthetase-like 1 Oasl1 21.2 13.3 7.3 21.8 298.0 80.6
Z-DNA binding protein 1 Zbp1 21.2 13.1 6.7 22.6 113.5 71.3
The absolute fold-change was determined using semi-quantitative RT-PCR on 5 genes from the 4 hour time point and compared to the microarray analysis. In all cases
numbers are relative to vehicle control.
doi:10.1371/journal.pone.0011031.t003
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Comp. Reg. Gene set name Genes NES FDR
A. vs V. +
A. vs V. 2
I. vs. V. + DEFENSE_RESPONSE 46/211 1.98 0.021
+ I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 27/100 1.92 0.032
+ HUMORAL_IMMUNE_RESPONSE 8/28 1.91 0.028
+ RESPONSE_TO_OTHER_ORGANISM 17/61 1.89 0.03
+ REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 23/82 1.88 0.026
+ IMMUNE_RESPONSE 40/198 1.88 0.025
+ INFLAMMATORY_RESPONSE 20/116 1.83 0.043
+ MEIOSIS_I 3/17 1.83 0.038
+ MULTI_ORGANISM_PROCESS 26/114 1.82 0.036
+ POSITIVE_REGULATION_OF_I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 21/78 1.82 0.033
+ MEIOTIC_RECOMBINATION 3/15 1.79 0.043
+ MEIOTIC_CELL_CYCLE 8/31 1.76 0.059
+ POSITIVE_REGULATION_OF_SIGNAL_TRANSDUCTION 22/113 1.75 0.065
+ JAK_STAT_CASCADE 10/28 1.75 0.065
+ RESPONSE_TO_VIRUS 13/40 1.74 0.068
+ CYTOKINE_AND_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY 5/16 1.73 0.069
+ PEPTIDYL_TYROSINE_MODIFICATION 3/27 1.71 0.077
+ RESPONSE_TO_BIOTIC_STIMULUS 22/91 1.7 0.082
+ DEFENSE_RESPONSE_TO_BACTERIUM 5/17 1.7 0.078
+ IMMUNE_SYSTEM_PROCESS 42/281 1.69 0.088
+ RESPONSE_TO_WOUNDING 24/169 1.68 0.086
+ REGULATION_OF_T_CELL_ACTIVATION 6/25 1.67 0.096
+ TRNA_METABOLIC_PROCESS 7/19 1.66 0.099
I. vs. V. 2 TRANSLATIONAL_INITIATION 10/25 21.8 0.051
2 REGULATION_OF_TRANSLATIONAL_INITIATION 8/20 21.84 0.055
2 NUCLEOTIDE_EXCISION_REPAIR 8/18 21.81 0.057
2 TRANSCRIPTION_FROM_RNA_POLYMERASE_III_PROMOTER 9/16 21.85 0.09
A.I. vs V. + DEFENSE_RESPONSE 52/211 1.96 0.062
+ RESPONSE_TO_OTHER_ORGANISM 12/61 1.92 0.073
A.I. vs V. 2
A.I. vs. I. +
A.I. vs. I. 2 GOLGI_VESICLE_TRANSPORT 27/45 22.43 0.000
2 ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT 10/16 22.24 0.000
2 SECRETORY_PATHWAY 25/78 22.18 0.000
2 MRNA_PROCESSING_GO_0006397 28/65 22.10 0.002
2 SECRETION_BY_CELL 28/105 22.07 0.002
2 RNA_SPLICING 30/81 21.98 0.010
2 MRNA_METABOLIC_PROCESS 29/73 21.97 0.010
2 RNA_PROCESSING 47/153 21.96 0.010
2 RNA_SPLICING__VIA_TRANSESTERIFICATION_REACTIONS 15/31 21.95 0.010
2 I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 34/100 21.85 0.033
2 SPLICEOSOME_ASSEMBLY 9/18 21.85 0.034
2 INTRACELLULAR_TRANSPORT 82/255 21.82 0.041
2 TRANSCRIPTION_INITIATION_FROM_RNA_POLYMERASE_II_PROMOTER 6/18 21.80 0.048
2 TRANSCRIPTION_INITIATION 7/24 21.74 0.082
A. =APAP, I. =IFN-b, V. =Vehicle, I.A. =IFN-b+APAP. Comp. =Comparison, Reg. =Regulation and ‘+’ indicates up-regulated and ‘2’indicates down-regulated.,
Genes=Genes Enriched/Total Genes in Set, NES=Normalized Enrichment Score, FDR=False Discovery Rate.
doi:10.1371/journal.pone.0011031.t005
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[51,52]. The induction of OR mRNAs has been observed in
previous studies examining the transcriptional response of
C57BL/6 mice to APAP-induced liver injury [53]. An early up-
regulation of chemosensory receptors following IFN-b+APAP
treatment may reflect an initial response to cellular stress or
conflicting stimuli.
By 4 hours post-treatment GPCRs were no longer identified
among GO terms. All of the OR GPCRs detected at the earlier
time point were considered up-regulated (FDR,0.05) at 4 hours,
but the majority remained below the 1.5-fold selection threshold.
This may coincide with an overall decrease in gene expression
following APAP treatment. By four hours post-treatment the list of
GO biological processes clustered through DAVID analysis were
predominately involved in mRNA transcription, processing and
translation. The down-regulation of genes involved in transcrip-
tion and mRNA processing could contribute to the observed
dampened transcriptional response.
A similar picture is provided by the GSEA analysis. Consistent
with the GO terms clustered using DAVID IFN-b treatment
predominately up-regulates genes in immune response pathways.
IFN-b treatment down-regulates gene sets involved in transcrip-
tion and translation. It is notable that few pathways are identified
at an FDR of 0.1 in the combined treatment group compared to
vehicle control, given how many significant differences we
observed in the gene-to-gene analysis. This is partly explained
when we extend our analyses to a higher FDR level of 0.25. In this
case we observe the positive enrichment of 6 additional immune
related pathways and extensive negative enrichment of pathways
related to protein synthesis, RNA transcription, RNA processing,
protein transport and protein modification in the IFN-b+APAP
group (data not shown).
When we directly compared the IFN-b+APAP treatment group
to IFN-b we found no pathways were up-regulated in the
combined treatment relative to IFN-b alone. We did observe the
down-regulation of 13 gene sets related to RNA transcription/
processing or protein transport. Additionally, the IkB/NF-kB
pathway was down-regulated due to the negative enrichment of 34
genes, four of which (MyD88, Trif, Traf2 and IkBKe) are also
involved in the activation of interferon regulatory factors.
Leading edge analysis (LEA) did not find any genes involved in
the NF-kB pathway. This was not surprising as LEA searches the
enriched pathways for genes that appear multiple times and 13 of
the 14 pathways down-regulated by IFN-b+APAP are involved in
either RNA processing or membrane trafficking events. The
observed comprehensive decrease in genes involved in RNA
processing suggests that overall protein synthesis is likely to be
diminished in hepatic cells during co-treatment. Additional
evidence for a decrease in protein synthesis may be provided by
the observed down-regulation of genes involved in retrograde
trafficking. One of the principle functions of the retrograde
trafficking system is to ensure ER-homeostasis and to retrieve
Golgi and pre-Golgi proteins. A reduction in protein synthesis
would decrease the need for retrograde trafficking components.
APAP modifies IFN-b-induced gene expression patterns in the
liver by activating genes involved in chemosensory or signal
transduction pathways and down-regulating genes involved in
cellular metabolism. The vast majority of genes that are
differentially regulated by IFN-b treatment alone remain tran-
scriptionally active during co-treatment. However, a marked shift
was observed in the Gene Ontology (GO) terms clustered by
DAVID. This is due in part to the application of a minimum 1.5-
fold change but is also due to an increase in the total number of
genes regulated by IFN-b+APAP as compared to IFN-b alone.
DAVID calculates an enrichment score based on a comparison
between the number of genes that cluster to a specific GO term
relative to the number of genes that would be expected to cluster
to that term based on random chance. For example, the GO
category apoptosis has an enrichment score of 1.02 based on the
up-regulation of 5 out of 70 genes by IFN-b treatment at 1.5 h.
The same GO term, apoptosis, only has an enrichment score of
0.62 based on the up-regulation of 12 out of 263 genes in the IFN-
b+APAP group. Therefore, despite the fact that the same genes
appear in both treatment groups the larger number of non-
apoptosis related genes that are also activated in the co-treatment
group result in a low enrichment score for the GO term apoptosis.
Another factor not considered by DAVID when analyzing
genetic data are changes in the fold-expression of IFN- b
responsive genes upon co-treatment with APAP. For example,
121 genes are responsive in the co-treatment group and the IFN-b
Figure 2. Leading edge analysis of genes downregulated by IFN-b + APAP treatment relative to IFN-b treatment at 4 h. A total of 178
genes contribute to the enrichment of 14 biological pathways down-regulated in the IFN-b + APAP treatment group relative to IFN-b alone. The 24
genes that participate in 5 or more of these pathways are shown.
doi:10.1371/journal.pone.0011031.g002
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though their categorical pattern of regulation remains the same
(less-positive or more-negative). This suggests that APAP modifies
the IFN-b response in a global and systemic fashion not considered
by DAVID. The mechanism of APAP-induced down-regulation is
unclear; it may involve one or more transcription factors normally
induced or repressed by IFN-b as well as the overall down-
regulation of genes whose products function in transcription and
translation.
This study examined gene expression profiles from the whole
murine liver. Changes in less abundant cell populations may not
have been detected and it is impossible to attribute the
observations to any one cell type. Previous studies combining
IFN-a and APAP found no evidence for a reduction in the
antiviral or anti-proliferative response of immortalized cell lines or
isolated PBMCs [19,54]. The global transcriptional change in a
heterogeneous cell population observed here may be driven by
different cell types. Alternatively, the in vitro antiviral response may
not be sensitive enough to detect the changes observed in this
study [19,54]. Our data indicate that APAP effects quantitative
but not qualitative changes to the expression patterns induced by
IFN-b. As such, APAP is more likely to lower the efficacy of IFN-b
treatment as opposed to abrogate a desired endpoint. Overall, this
data fits with a recent study which demonstrated that children who
were treated prophylactically with acetaminophen during vacci-
nation had diminished antibody titers, although the majority had
successful vaccine responses [13]. The results presented here
suggest that a dampened NF-kB response in response to APAP co-
treatment may have had a role in this outcome.
In conclusion, we demonstrate that APAP administered during
recombinant IFN-b treatment induces a broad change in the
transcriptional profile of hepatic genes. These expression changes
have the potential to modify the IFN-b response and may explain
occasional APAP-mediated hepatotoxicity observed in patients
when recombinant interferon is combined with a tertiary
treatment [55]. More importantly, this research suggests that the
casual administration of APAP alongside IFN-b may result in
unintended dampening of the transcriptional response and may
reduce the efficacy of IFN-b treatment.
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